Dermbits

Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions

Dr Bhutani-Jacques on Psoriasis (October 2026)

When you're considering tildrakizumab for a patient with psoriasis, how does its HCP-administered model factor into your treatment decision?
Oct 2, 2026Psoriasis

When you're considering tildrakizumab for a patient with psoriasis, how does its HCP-administered model factor into your treatment decision?

-

What have you learned from patients who seemed well suited to self-administration initially but encountered challenges once treatment was underway?
Oct 2, 2026Psoriasis

What have you learned from patients who seemed well suited to self-administration initially but encountered challenges once treatment was underway?

-

What does HCP administration allow you to know about a patient's treatment that can be harder to assess with a self-administered biologic?
Oct 2, 2026Psoriasis

What does HCP administration allow you to know about a patient's treatment that can be harder to assess with a self-administered biologic?

-

What assumptions do clinicians sometimes make about patients' preference for self-administration that don't necessarily hold true in practice?
Oct 2, 2026Psoriasis

What assumptions do clinicians sometimes make about patients' preference for self-administration that don't necessarily hold true in practice?

-

When patients are doing well on biologic therapy, how do you maintain meaningful clinical engagement without creating unnecessary treatment burden?
Oct 2, 2026Psoriasis

When patients are doing well on biologic therapy, how do you maintain meaningful clinical engagement without creating unnecessary treatment burden?

-

When clinicians and patients have different priorities around how a treatment is administered, how do you navigate that conversation?
Oct 2, 2026Psoriasis

When clinicians and patients have different priorities around how a treatment is administered, how do you navigate that conversation?

-